RESUMEN
A previous dose-finding study has suggested that romiplostim is effective in patients with refractory aplastic anaemia (AA) and 10 µg/kg once weekly was recommended as a starting dose. In this Phase II/III, multicentre, open-label study, romiplostim was administered subcutaneously at a fixed dose of 10 µg/kg once weekly for 4 weeks (weeks 1-4) followed by weekly doses (5, 10, 15 and 20 µg/kg) titrated by platelet response for up to 52 weeks (weeks 5-52). A total of 31 patients with AA who were refractory to immunosuppressive therapy (IST) and thrombocytopenia (platelet count of ≤30 × 109 /l) were enrolled. The primary efficacy endpoint of the proportion of patients achieving any haematological (platelet, neutrophil and erythrocyte) response at week 27 was 84% [95% confidence interval (CI) 66-95%]. Trilineage response was 39% (95% CI 22-58%) at week 53. The most common treatment-related adverse events (AEs) were headache and muscle spasms (each 13%). All AEs were mild or moderate except for three patients with Grade 3 hepatic AEs; no AEs necessitated romiplostim discontinuation. Two patients developed cytogenetic abnormalities, of whom one returned to normal karyotype at last follow-up. High-dose romiplostim is effective and well tolerated in the treatment of patients with AA refractory to IST.
Asunto(s)
Anemia Aplásica/tratamiento farmacológico , Anemia Refractaria/tratamiento farmacológico , Receptores Fc/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Trombopoyetina/uso terapéutico , Adulto , Anciano , Anemia Aplásica/sangre , Anemia Refractaria/sangre , Recuento de Células Sanguíneas , Femenino , Cefalea/inducido químicamente , Hematopoyesis/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Receptores Fc/administración & dosificación , Receptores Fc/sangre , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/efectos adversos , Proteínas Recombinantes de Fusión/sangre , Espasmo/inducido químicamente , Trombopoyetina/administración & dosificación , Trombopoyetina/efectos adversos , Trombopoyetina/sangre , Resultado del Tratamiento , Adulto JovenRESUMEN
DISEASE OVERVIEW: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS-RS) and RARS with thrombocytosis (RARS-T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T). DIAGNOSIS: MDS-RS is a lower-risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥ 15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN-RS-T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS-RS-SLD, along with a platelet count ≥450 × 10(9)/L and large atypical megakaryocytes. MUTATIONS AND KARYOTYPE: Mutations in SF3B1 are seen in ≥80% of patients with MDS-RS-SLD and MDS/MPN-RS-T, and strongly correlate with the presence of BM RS; MDS/MPN-RS-T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations. Cytogenetic abnormalities are uncommon in both. RISK STRATIFICATION: Most patients with MDS-RS-SLD are stratified into lower-risk groups by the revised-IPSS. Disease outcome in MDS/MPN-RS-T is better than that of MDS-RS-SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemic transformation. TREATMENT: Anemia and iron overload are complications seen in both and are managed similar to lower-risk MDS and MPN. The advent of luspatercept, a first-in-class erythroid maturation agent will tremendously boost the ability to manage anemia. Aspirin therapy is reasonable in MDS/MPN-RS-T, especially in the presence of JAK2V617F, but the value of platelet-lowering drugs remains uncertain.
Asunto(s)
Anemia Refractaria , Mutación , Anemia Refractaria/sangre , Anemia Refractaria/diagnóstico , Anemia Refractaria/genética , Anemia Refractaria/terapia , Anemia Sideroblástica/sangre , Anemia Sideroblástica/diagnóstico , Anemia Sideroblástica/genética , Anemia Sideroblástica/terapia , Eritroblastos/metabolismo , Femenino , Humanos , Sobrecarga de Hierro/sangre , Sobrecarga de Hierro/diagnóstico , Sobrecarga de Hierro/genética , Sobrecarga de Hierro/terapia , Masculino , Enfermedades Mielodisplásicas-Mieloproliferativas , Trombocitosis/sangre , Trombocitosis/diagnóstico , Trombocitosis/genética , Trombocitosis/terapiaRESUMEN
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease presenting with variable and various clinical findings. PNH might be overlooked and diagnosis may be delayed due to low awareness about PNH. This is the first multicenter study in Turkey, investigating the efficiency of diagnostic screening of PNH by multiparameter flow cytometry (FCM) according to consensus guidelines. METHODS: We evaluate the efficiency of consensus clinical indications for PNH testing with FCM in 1689peripheral blood samples from 20 centers between January 2014 and December 2017. RESULTS: Overall, at the 20 centers contributing to this study, PNH clone were detected in 62/1689 samples (3.6%) by FCM test. 75.8% (nâ¯=â¯47) of patients with PNH clone had aplastic anemia, 3.2% (nâ¯=â¯2) had Coombs (-) hemolytic anemia, 6.5% (nâ¯=â¯4) had unexplained cytopenia, 3.2% (nâ¯=â¯2) had MDS with refractory anemia, 1.6% (nâ¯=â¯1) had hemoglobinuria and 9.7% (nâ¯=â¯6) had others (elevated LDH, splenomegaly, etc.). In contrast, we detect no PNH clone test in patients who were screened for unexplained thrombosis. CONCLUSIONS: Our study showed that current clinical indications for PNH testing are highly efficient and diagnostic screening of suspected patients for PNH with FCM is recommended. However, advanced screening algorithms are required for patients presenting with unexplained thrombosis and normal complete blood count.
Asunto(s)
Anemia Refractaria , Prueba de Coombs , Citometría de Flujo , Hemoglobinuria Paroxística , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anemia Refractaria/sangre , Anemia Refractaria/diagnóstico , Femenino , Hemoglobinuria Paroxística/sangre , Hemoglobinuria Paroxística/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , TurquíaRESUMEN
Although azacitidine is the first-line drug for higher-risk myelodysplastic syndrome (MDS) patients, its efficacy for lower-risk MDS remains unestablished. Therefore, we conducted a prospective study to examine the efficacy and safety of a 5-day regimen of azacitidine (AZA-5) for lower-risk MDS. The primary endpoint was hematological improvement (HI) after 4 courses of therapy. A total of 51 patients with lower-risk MDS based on the French-American-British (FAB) classification (44 patients with refractory anemia [RA] and 7 patients with refractory anemia with ringed sideroblasts [RARS]) were enrolled from 6 centers in Japan. The median age was 75 years (range: 51-88). These patients received AZA-5 (75 mg/m2 ; once daily for 5 sequential days). The median number of AZA-5 courses was 8 (range: 1-57), and 45 patients (88.2%) received more than 4 courses. HI and transfusion independency were seen in 24 patients (47.1%) and 11 patients (39.2%), respectively. A total of 11 patients (21.6%) achieved complete remission or marrow remission. WT1 mRNA levels were not significantly correlated with therapy response. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 26 (51.0%) and 11 (21.5%) patients, respectively. Nonhematological grade 3 or 4 adverse events were observed in 9 patients (17.6%). Together, these results indicate that AZA-5 is feasible and effective for lower-risk MDS patients as well as for higher-risk MDS patients.
Asunto(s)
Anemia Refractaria/tratamiento farmacológico , Anemia Sideroblástica/tratamiento farmacológico , Antimetabolitos Antineoplásicos/uso terapéutico , Azacitidina/uso terapéutico , Anciano , Anciano de 80 o más Años , Anemia Refractaria/sangre , Anemia Sideroblástica/sangre , Transfusión de Componentes Sanguíneos/estadística & datos numéricos , Esquema de Medicación , Estudios de Factibilidad , Neutropenia Febril/inducido químicamente , Neutropenia Febril/epidemiología , Femenino , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Trombocitopenia/inducido químicamente , Trombocitopenia/epidemiología , Resultado del TratamientoRESUMEN
Refractory anaemia with ring sideroblasts (RARS) is distinguished by hyperplastic inefficient erythropoiesis, aberrant mitochondrial ferritin accumulation and anaemia. Heterozygous mutations in the spliceosome gene SF3B1 are found in a majority of RARS cases. To explore the link between SF3B1 mutations and anaemia, we studied mutated RARS CD34(+) marrow cells with regard to transcriptome sequencing, splice patterns and mutational allele burden during erythroid differentiation. Transcriptome profiling during early erythroid differentiation revealed a marked up-regulation of genes involved in haemoglobin synthesis and in the oxidative phosphorylation process, and down-regulation of mitochondrial ABC transporters compared to normal bone marrow. Moreover, mis-splicing of genes involved in transcription regulation, particularly haemoglobin synthesis, was confirmed, indicating a compromised haemoglobinization during RARS erythropoiesis. In order to define the phase during which erythroid maturation of SF3B1 mutated cells is most affected, we assessed allele burden during erythroid differentiation in vitro and in vivo and found that SF3B1 mutated erythroblasts showed stable expansion until late erythroblast stage but that terminal maturation to reticulocytes was significantly reduced. In conclusion, SF3B1 mutated RARS progenitors display impaired splicing with potential downstream consequences for genes of key importance for haemoglobin synthesis and terminal erythroid differentiation.
Asunto(s)
Anemia Refractaria/genética , Anemia Sideroblástica/genética , Eritropoyesis/genética , Hemoglobinas/biosíntesis , Fosfoproteínas/genética , Empalme del ARN/genética , Ribonucleoproteína Nuclear Pequeña U2/genética , Anciano , Anciano de 80 o más Años , Anemia Refractaria/sangre , Anemia Sideroblástica/sangre , Transporte Biológico/genética , Perfilación de la Expresión Génica , Genes Supresores de Tumor , Heterogeneidad Genética , Humanos , Hierro/metabolismo , Fosfoproteínas/fisiología , Isoformas de Proteínas/genética , Factores de Empalme de ARN , ARN Mensajero/genética , Ribonucleoproteína Nuclear Pequeña U2/fisiología , Análisis de Secuencia de ARN , Transducción de Señal/genéticaRESUMEN
Myelodysplastic syndromes (MDS) are heterogeneous clonal disorders characterized by cytopenias that arise due to ineffective haematopoiesis and morphological dysplasia and carry an increased risk of incident acute myeloid leukaemia. The pathogenesis of marrow dysfunction in MDS is multifactorial and consistent with a multistep model and may lead to heterogeneity of MDS. We investigated the proteome profile of circulating neutrophils purified from patients with refractory cytopenia with multilineage dysplasia (RCMD) to identify proteins that have a role in the pathogenesis. Using 2-dimensional difference gel electrophoresis and protein identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, we found that peroxiredoxin 2 (PRDX2), a member of the peroxiredoxin family that regulates reactive oxygen species, was markedly upregulated in neutrophils of RCMD patients compared to healthy donors. Increased PRDX2 expression in the neutrophils of RCMD patients was confirmed using quantitative reverse transcription polymerase chain reaction, immunoblotting and immunocytochemical analysis. In addition, white blood cell and neutrophil counts in RCMD patients correlated inversely with the PRDX2 expression of. Oxidative stress is a known factor involved in the pathogenesis of MDS, and PRDX2 is associated with tumourigenesis of several solid tumours. Accordingly, our results suggest that PRDX2 may perform an important function in the pathogeneis of RCMD.
Asunto(s)
Anemia Refractaria/sangre , Neutrófilos/metabolismo , Peroxirredoxinas/biosíntesis , Adulto , Anciano , Anciano de 80 o más Años , Anemia Refractaria/genética , Anemia Refractaria/patología , Linaje de la Célula , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neutrófilos/patología , Peroxirredoxinas/genética , Pronóstico , ProteómicaRESUMEN
To evaluate the roles of apoptotic cells in peripheral blood (PB) on multiple organ injury, five patients with hematopoietic stem cell transplantation (HSCT) and one with refractory anemia were examined. The following findings were confirmed. 1) High-dose alkylating agents were administrated as conditioning regimens to all HSCT patients. 2) Many organs were injured in all cases. 3) Neutrophils accumulated in the capillaries of injured organs, and endothelial cells were extensively injured. 4) Large numbers of apoptotic cells and γH2AX(+) cells were observed in the foci of large cells with hyperchromatic nuclei. 5) Increased numbers of apoptotic cells (6/6), γH2AX(+) cells (6/6), scavenger receptor A positive (SRA(+) ) cells (6/6), and tumor necrosis factor (TNF)-α(+) cells (5/6) were observed in PB smear preparations. 6) Cytokines exceeded the normal levels in most patients. From these findings, apoptotic cells were considered to be produced by the administration of high-dose alkylating agents in HSCT patients, and apoptotic cells and SRA(+) cells in PB were thought to play important roles in the development of multiple organ injury in HSCT and MDS patients.
Asunto(s)
Anemia Refractaria/sangre , Apoptosis/fisiología , Insuficiencia Multiorgánica/sangre , Insuficiencia Multiorgánica/patología , Adulto , Anciano de 80 o más Años , Alquilantes/farmacología , Anemia Refractaria/patología , Anemia Refractaria/cirugía , Apoptosis/efectos de los fármacos , Citocinas/sangre , Relación Dosis-Respuesta a Droga , Trasplante de Células Madre Hematopoyéticas , Humanos , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/cirugía , Neutrófilos/metabolismo , Neutrófilos/patología , Receptores Depuradores de Clase A/metabolismo , Acondicionamiento Pretrasplante/métodosRESUMEN
Pyridoxine, or vitamin B6, is commonly used to treat acquired idiopathic sideroblastic anaemia (AISA, including refractory anaemia with ring sideroblasts), but the efficacy of this therapy in an unselected AISA population (i.e. patients without confirmed ALAS2 or other pyridoxine-responsive germline mutations) has not been established. We reviewed clinical data from 231 patients with AISA and found that 42% of 203 evaluable patients had been treated with pyridoxine. Only 6.8% of pyridoxine-treated patients experienced a haemoglobin improvement (≥ 1.5 g/dL) meeting 2006 International Working Group for Myelodysplastic Syndromes standardised response criteria. As some patients received combination therapy with erythropoietin or other agents, improvement could be attributed to pyridoxine monotherapy in only one patient (1.4%). Smaller, less meaningful increments in haemoglobin levels of 0.5 g/dL were observed in 13.5% of patients. Response to therapy did not correlate with International Prognostic Scoring System (IPSS) risk group or multilineage vs unilineage dysplasia. New symptomatic peripheral neuropathy was noted in 2.3% of patients treated with pyridoxine. In this large series of unselected patients with sideroblastic anaemia, pyridoxine therapy was ineffective and was associated with a risk of adverse effects. Pyridoxine therapy should be reserved for patients with known or suspected pyridoxine-responsive mutations.
Asunto(s)
Anemia Refractaria/tratamiento farmacológico , Anemia Sideroblástica/tratamiento farmacológico , Piridoxina/uso terapéutico , 5-Aminolevulinato Sintetasa/genética , Adulto , Anciano , Anciano de 80 o más Años , Anemia Refractaria/sangre , Anemia Refractaria/genética , Anemia Sideroblástica/sangre , Anemia Sideroblástica/genética , Femenino , Hemoglobinas/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Mutación , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Pronóstico , Piridoxina/efectos adversos , Estudios Retrospectivos , Insuficiencia del Tratamiento , Resultado del TratamientoRESUMEN
Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder characterized by iron deficiency anemia unresponsive to oral iron treatment but partially responsive to parenteral iron therapy. IRIDA has recently been shown to be caused by mutations in the gene TMPRSS6, which encodes a transmembrane serine protease (also known as matriptase-2) expressed by the liver. IRIDA patients show inappropriately elevated levels of hepcidin, a circulating hormone produced by the liver that inhibits both iron absorption from the intestine and iron release from macrophage stores. Recent studies suggest that TMPRSS6 normally acts to downregulate hepcidin expression by cleaving hemojuvelin, a membrane-bound protein that promotes hepcidin signaling in hepatocytes. A discussion of the clinical presentation of IRIDA, the molecular genetics of this disorder, and recent studies elucidating the underlying pathophysiology are presented.
Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Anemia Refractaria/tratamiento farmacológico , Hematínicos/administración & dosificación , Compuestos de Hierro/administración & dosificación , Hierro/metabolismo , Hígado/metabolismo , Administración Oral , Anemia Ferropénica/sangre , Anemia Ferropénica/genética , Anemia Ferropénica/fisiopatología , Anemia Refractaria/sangre , Anemia Refractaria/genética , Anemia Refractaria/fisiopatología , Péptidos Catiónicos Antimicrobianos/sangre , Niño , Preescolar , Femenino , Proteínas Ligadas a GPI , Proteína de la Hemocromatosis , Hepcidinas , Humanos , Lactante , Infusiones Parenterales , Hierro/sangre , Masculino , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Mutación , Serina Endopeptidasas/genética , Insuficiencia del Tratamiento , Regulación hacia ArribaRESUMEN
We carried out the cytogenetic investigation of bone marrow aspirate from 32 patients with different types of MDS. The patients were from 8 regions of Ukraine. 11 patients had abnormal karyotype, and the transformation to AML were observed in 5 of them (45.5%). 27% of all patients had chromosomal changes with 3 or more chromosomes involved. The highest percentage of the patients with chromosomal anomalies (66.7%) was in cases of RAEB. Chromosome deletions were the most frequently detected karyotype abnormalities. We consider the phenomenon of chromosome fragmentation as the cytogenetic approval of the increased level of apoptosis in patients with MDS. The risk of the transformation to AML was measured using new international score system IPSS.
Asunto(s)
Aberraciones Cromosómicas , Síndromes Mielodisplásicos/genética , Adulto , Anciano , Anemia Refractaria/sangre , Anemia Refractaria/genética , Anemia Refractaria/mortalidad , Anemia Refractaria/patología , Apoptosis/genética , Células de la Médula Ósea/patología , Análisis Citogenético , Fragmentación del ADN , Femenino , Humanos , Cariotipificación , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/sangre , Síndromes Mielodisplásicos/mortalidad , Síndromes Mielodisplásicos/patología , Valor Predictivo de las Pruebas , UcraniaAsunto(s)
Anemia Refractaria/etiología , Anemia Refractaria/terapia , Péptidos Catiónicos Antimicrobianos/sangre , Implantación de Prótesis de Válvulas Cardíacas , Insuficiencia de la Válvula Tricúspide/complicaciones , Insuficiencia de la Válvula Tricúspide/cirugía , Anemia Refractaria/sangre , Eritropoyetina/uso terapéutico , Femenino , Hepcidinas , Humanos , Hierro/sangre , Persona de Mediana Edad , Válvula Mitral , Proteínas Recombinantes/uso terapéutico , Válvula Tricúspide , Insuficiencia de la Válvula Tricúspide/sangreAsunto(s)
Acetamidas/efectos adversos , Anemia Refractaria/inducido químicamente , Anemia Sideroblástica/inducido químicamente , Antibacterianos/efectos adversos , Oxazolidinonas/efectos adversos , Complicaciones Posoperatorias/inducido químicamente , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Acetamidas/uso terapéutico , Anciano , Anemia Refractaria/sangre , Anemia Refractaria/diagnóstico , Anemia Refractaria/tratamiento farmacológico , Anemia Refractaria/terapia , Anemia Sideroblástica/sangre , Anemia Sideroblástica/diagnóstico , Anemia Sideroblástica/tratamiento farmacológico , Anemia Sideroblástica/terapia , Antibacterianos/uso terapéutico , Artroplastia , Artroplastia de Reemplazo de Cadera , Artroplastia de Reemplazo de Rodilla , Terapia Combinada , Comorbilidad , Diabetes Mellitus Tipo 2/complicaciones , Diagnóstico Diferencial , Transfusión de Eritrocitos , Eritropoyetina/uso terapéutico , Femenino , Humanos , Linezolid , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Obesidad Mórbida/complicaciones , Oxazolidinonas/uso terapéutico , Polifarmacia , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/tratamiento farmacológico , Complicaciones Posoperatorias/terapia , Infecciones Relacionadas con Prótesis/microbiología , Infecciones Relacionadas con Prótesis/cirugía , ReoperaciónRESUMEN
Multiple primary malignant neoplasms (MPMNs) are rare malignant neoplasms that simultaneously or successively occur in the same patient as 2 or more primary malignancies. Currently, an increasing number of cases are being reported. In general, MPMNs more commonly occur as 2 solid tumors or 2 hematological malignancies. Cases of MPMN that involve a solid tumor and a hematological malignancy are rare. Here, we report a case of synchronous colorectal cancer (CRC) and multiple myeloma (MM) with chest wall involvement. After reviewing the literature, we believe that there may be a distinct syndrome involving CRC and MM. The patient in our case study suffered refractory anemia following surgery and 2 cycles of chemotherapy. Initially, the anemia was considered to be a common manifestation of CRC in this patient. Interestingly, although he received a blood transfusion, his hemoglobin levels remained low. He later developed hematuria, proteinuria, multiple osteoporosis in the costal bones, and thrombocytopenia. These new symptoms drew our attention, and we considered a diagnosis of synchronous primary CRC and MM, with the anemia as a symptom of MM. Based on the results of a bone marrow aspirate, MM was confirmed. Therefore, when CRC is associated with refractory anemia, we should not only assume that anemia is a classical symptom of CRC, a result of chronic blood loss, nutritional deficiencies, or myelosuppression due to chemotherapy, but we should also consider that it may reflect the possibility of a coexisting hematologic malignancy. As the treatment of these 2 malignancies is different, early diagnosis and treatment based on definitive diagnosis as early as possible will be beneficial to overall prognosis.
Asunto(s)
Adenocarcinoma/terapia , Anemia Refractaria/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias Colorrectales/terapia , Mieloma Múltiple/terapia , Neoplasias Primarias Múltiples/terapia , Adenocarcinoma/sangre , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Anemia Refractaria/sangre , Anemia Refractaria/diagnóstico , Anemia Refractaria/etiología , Biopsia , Quimioterapia Adyuvante/efectos adversos , Colectomía , Colonoscopía , Neoplasias Colorrectales/sangre , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/patología , Detección Precoz del Cáncer , Fluorouracilo/efectos adversos , Humanos , Leucovorina/efectos adversos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/sangre , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/patología , Neoplasias Primarias Múltiples/sangre , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Primarias Múltiples/patología , Compuestos Organoplatinos/efectos adversos , Pronóstico , Síndrome , Pared Torácica/patología , Tomografía Computarizada por Rayos XRESUMEN
Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associated tyrosine kinase in patients with polycythemia vera (PV) and other BCR/ABL-negative myeloproliferative disorders prompted many groups around the world to examine diverse subsets of patients with myeloid diseases for the prevalence of the JAK2 V617F mutation and its clinical and pathological associations.
Asunto(s)
Anemia Refractaria/genética , Anemia Sideroblástica/genética , Janus Quinasa 2/genética , Mutación Missense , Mutación Puntual , Receptores de Trombopoyetina/genética , Anciano de 80 o más Años , Anemia Refractaria/sangre , Anemia Refractaria/clasificación , Anemia Sideroblástica/sangre , Animales , Análisis Mutacional de ADN , Activación Enzimática/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recuento de PlaquetasRESUMEN
A clonal origin of hematopoiesis was studied by investigation of X-chromosome inactivation patterns (XCIP) in isolated granulocyte, CD14(+) and CD3(+) subpopulations obtained from bone marrow and peripheral blood of 36 female patients with primary myelodysplastic syndrome (MDS). Clonality was assessed by PCR amplification of polymorphic short tandem repeats of the human androgen receptor (HUMARA) gene and by investigation of silent polymorphism of iduronate sulphatase (IDS) or p55 genes. On the basis of results in a control group of 20 healthy age related females, a ratio of at least 9:1 between the two alleles was considered a significant marker of monoclonal hematopoiesis. Ten of the 11 patients with advanced forms of MDS (RAEB, RAEB-T, CMML) had clonal granulocytes and CD14(+) cells in peripheral blood. In patients with early disease, only 2 out of 11 patients (18%) with RA or RARS, according to WHO classification, had clonal granulocytes and CD14(+) cells in peripheral blood and bone marrow and 2 other patients with 5q-syndrome exhibited extremely oligoclonal granulocyte subpopulation in bone marrow. In contrast, we found clonal granulocytes in 12 out of 14 patients (86%) with refractory cytopenia with multilineage dysplasia (RCMD) and 8 of them simultanously exhibited clonal CD14(+) cells. Estimated 3 years survival of patients with early disease and clonal cell subpopulations was 61% as compared with 88% in patients without clonal hematopoiesis. Karyotype abnormalities were detected in 11 of the 25 females with early disease. Clonal patterns were present in 7 out of 8 patients with abberations diagnosed by routine cytogenetics, nevertheless, FISH revealed 5q deletion in 3 patients without signs of clonality in XCIP assay. No correlation was found between the presence of clonal subpopulations and the degree of telomere shortening in early MDS. Despite some limitations, the measurement of XCIP remains a sensitive tool for diagnosis of the first transforming mutation in the clonal development of MDS especially when combined with FISH and when an age related group is used to establish an appropriate allele ratio to exclude constitutional or acquired skewing. The occurrence of clonal cell subpopulations in most of the RCMD patients in contrast to RA may reflect a proposed multistep pathogenesis of MDS with dysplastic changes limited to erythropoiesis in early step and with subsequent development of multilineage dysplasia. The results also support the usefulness of separation of RCMD from 'pure' RA; however, a more complex insight combining different molecular techniques performed in a large number of patients is needed for refined classification of MDS on the basis of new molecular prognostic factors and for indication of more effective targeted therapy.
Asunto(s)
Anemia Refractaria/patología , Médula Ósea/patología , Síndromes Mielodisplásicos/clasificación , Síndromes Mielodisplásicos/patología , Anemia Refractaria/sangre , Anemia Refractaria/clasificación , Anemia Refractaria/genética , Bandeo Cromosómico , Femenino , Humanos , Hibridación Fluorescente in Situ , Síndromes Mielodisplásicos/sangre , Síndromes Mielodisplásicos/genética , Valores de Referencia , Telómero/ultraestructuraAsunto(s)
Fosfatasa Alcalina/sangre , Leucocitos/enzimología , Síndromes Mielodisplásicos/enzimología , Síndromes Mielodisplásicos/patología , Anemia Refractaria/sangre , Anemia Refractaria/enzimología , Anemia Refractaria/patología , Anemia Refractaria con Exceso de Blastos/sangre , Anemia Refractaria con Exceso de Blastos/enzimología , Anemia Refractaria con Exceso de Blastos/patología , Crisis Blástica/sangre , Crisis Blástica/enzimología , Crisis Blástica/patología , Células de la Médula Ósea/patología , Humanos , Síndromes Mielodisplásicos/sangreRESUMEN
Interferon-alpha has been used as a differentiating agent in the treatment of patients with myelodysplastic syndrome with conflicting results and often significant toxicity. In order to maximize the differentiating effects of this agent and minimize the myelosuppressive effects, a prospective pilot study was initiated utilizing interferon alpha-2a (Roferon A, Roche Laboratories) in the treatment of complicated or poor prognosis myelodysplasia. The study regimen utilized 'mini-dose' interferon alpha-2a at 1 x 10(6) units subcutaneously three-times per week for 16 weeks followed by an 8 week observation period. Nine patients were enrolled between May 1990 and June 1991, of which seven are evaluable. Forty-three percent (3/7) had a partial or clinical response as defined by normalization of one or more of the hemoglobin concentration, white blood cell count, or platelet count, or a decrease in transfusion requirement by > or = 50%. Only one patient was removed from study for interferon-associated toxicity. Mini-dose interferon alpha-2a appears to be an effective regimen for some patients with myelodysplasia which can be administered with minimal toxicity. Further investigation with interferon-alpha for the treatment of myelodysplastic syndrome, at the dosage utilized in this study, is warranted.
Asunto(s)
Anemia Refractaria/terapia , Interferón-alfa/administración & dosificación , Leucemia Mielomonocítica Crónica/terapia , Anemia Refractaria/sangre , Anemia Refractaria con Exceso de Blastos/terapia , Transfusión de Componentes Sanguíneos , Humanos , Interferón alfa-2 , Leucemia Mielomonocítica Crónica/sangre , Proyectos Piloto , Pronóstico , Estudios Prospectivos , Proteínas Recombinantes , Inducción de RemisiónRESUMEN
Myelodysplastic syndromes (MDS) characterized by multilineage cytopenias and dysplasia but lacking an increase in blasts, with no Auer rods or monocytosis, do not exactly fit any of the categories of the French-American-British (FAB) classification of MDS and are often diagnosed as refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), or 'unclassifiable' MDS. It has been suggested that these 'unclassifiable' cases form a distinct subset with a clinical behavior more like that of refractory anemia with excess of blasts (RAEB) than that of RA or RARS, but few studies have been undertaken that characterize this group. We compared the clinical, hematologic, morphologic and cytogenetic features of 18 such patients - for whose disease we propose the designation 'refractory cytopenia with multilineage dysplasia' (RCMD) - to those of 42 patients meeting the FAB criteria for RA or RARS (14 patients) and RAEB (28 patients). Our results show that cytopenias in RCMD are more severe than those in RA or RARS, but are similar to those in RAEB. Erythroid hyperplasia and dyserythropoiesis are the main findings in bone marrow specimens of RA or RARS, but the major features in RCMD are multilineage proliferation and dysplasia, which, except for the lack of increased blasts resemble the findings in RAEB. Only 1/14 patients (7%) with RA or RARS had an abnormal karyotype, whereas RCMD resembled RAEB in terms of the frequency (41 vs 50%, respectively) and type of karyotypic lesions. Abnormalities of chromosomes 5 and 7 (excluding del(5q) as an isolated finding) or complex aberrations were seen only in RCMD and RAEB. in RCMD, the median survival was 24 months, with a 4-year survival rate of48 +/- 13%, intermediate between the findings in RA/RARS (107 months and 77 +/- 12%, respectively) and RAEB (18 months and 27 +/- 9%, respectively). Our data indicate that RCMD is a distinct subset of MDS, with an unfavorable clinical outcome. The designation 'refractory cytopenia with multilineage dysplasia' emphasizes the differences between such cases and the primarily dyserythropoietic, indolent subgroups of MDS, such as RA or RARS.